Knights of Columbus Asset Advisors LLC Acquires 124,396 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Knights of Columbus Asset Advisors LLC increased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 420.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 153,949 shares of the company's stock after purchasing an additional 124,396 shares during the period. Knights of Columbus Asset Advisors LLC owned approximately 0.29% of Viridian Therapeutics worth $3,353,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in VRDN. Alliancebernstein L.P. acquired a new stake in Viridian Therapeutics during the fourth quarter worth approximately $26,985,000. State Street Corp grew its stake in Viridian Therapeutics by 159.0% in the third quarter. State Street Corp now owns 1,178,549 shares of the company's stock valued at $24,172,000 after acquiring an additional 723,484 shares during the period. BlackRock Inc. grew its stake in Viridian Therapeutics by 39.3% in the third quarter. BlackRock Inc. now owns 1,982,062 shares of the company's stock valued at $40,653,000 after acquiring an additional 559,238 shares during the period. Braidwell LP grew its stake in Viridian Therapeutics by 43.8% in the third quarter. Braidwell LP now owns 1,735,182 shares of the company's stock valued at $26,618,000 after acquiring an additional 528,882 shares during the period. Finally, Perceptive Advisors LLC grew its stake in Viridian Therapeutics by 42.3% in the first quarter. Perceptive Advisors LLC now owns 1,736,386 shares of the company's stock valued at $44,174,000 after acquiring an additional 515,811 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts have commented on VRDN shares. HC Wainwright reissued a "buy" rating and issued a $37.00 price objective on shares of Viridian Therapeutics in a research note on Thursday, February 29th. Needham & Company LLC reissued a "buy" rating and issued a $30.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday, March 20th. B. Riley reduced their price objective on Viridian Therapeutics from $29.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, March 21st. Finally, Wedbush raised their price objective on Viridian Therapeutics from $39.00 to $40.00 and gave the company an "outperform" rating in a research note on Wednesday, February 28th. Ten analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $36.60.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock traded down $0.56 during mid-day trading on Friday, reaching $14.60. 1,489,694 shares of the company's stock were exchanged, compared to its average volume of 696,335. The business's fifty day simple moving average is $17.70 and its 200 day simple moving average is $17.55. The firm has a market capitalization of $916.44 million, a PE ratio of -2.74 and a beta of 1.07. Viridian Therapeutics, Inc. has a one year low of $10.93 and a one year high of $30.30. The company has a quick ratio of 18.26, a current ratio of 18.26 and a debt-to-equity ratio of 0.09.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($1.35) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.37). The business had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.15 million. Viridian Therapeutics had a negative return on equity of 121.80% and a negative net margin of 75,711.48%. The business's revenue was down 31.4% compared to the same quarter last year. During the same quarter last year, the business posted ($1.13) earnings per share. On average, sell-side analysts expect that Viridian Therapeutics, Inc. will post -4.39 earnings per share for the current year.

Insider Buying and Selling

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc purchased 476,190 shares of the company's stock in a transaction that occurred on Monday, January 22nd. The shares were acquired at an average cost of $21.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the director now owns 1,839,954 shares of the company's stock, valued at approximately $38,639,034. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.43% of the stock is currently owned by corporate insiders.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.